TRUST

TRUST

Lumos-T Safely Reduces Routine Office Device Follow-Up

Study Design

  • Multi-center, prospective, randomized study
  • To demonstrate that BIOTRONIK Home Monitoring can safely reduce in-office follow-ups.
  • 1.450 patients enrolled at 102 centers in USA

Key Result 1

TRUST demonstrated equal safety event rate in both groups. BIOTRONIK Home Monitoring delivered a reduction of 45% of in-office follow-up visits.

圖片
Grafic about mean number of in-office follow-up visits per patient /year

Key Result 2

BIOTRONIK Home Monitoring delivered a significant gain in early detection of clinically relevant symptomatic and asymptomatic events

圖片
Early detection- Asymptomatic and all arrhythmia event

Key Result 3

BIOTRONIK Home Monitoring significantly reduced the time to evaluation of clinically relevant tachyarrhythmia events

圖片
Early detection of clinically relevant tacchyarrhythmia events

Clinical Relevance

  • The TRUST trial is the first and largest clinical study of its kind. It has clinically proven the safety and effectiveness of BIOTRONIK Home Monitoring.
  • Results unequivocally establish BIOTRONIK Home Monitoring as a highly effective method of follow-up. Patients' safety is enhanced by enabling prompt medical care if problems occur in either their clinical condition or in their devices.
Reference no.
undefinedundefined
1 Endpoint
  • To compare the number of in-office follow-ups for patients in BIOTRONIK Home Monitoring group vs. Control group
  • To compare the composite safety event rate (SER) between the two groups:
  • Death, Incidence of stroke, Events requiring surgical
undefinedundefined
2 Endpoint
  • To demonstrate that BIOTRONIK Home Monitoring provides early detection of VF, VT, SVT, and AF events and to demonstrate that BIOTRONIK Home Monitoring can be used to triage patient-initiated calls such as those following device therapy delivery, resulting in lower utilization of ER/clinic visits
  • Early detection: To compare the time from onset to evaluation of VF, VT, SVT and AF events between the two groups
  • Remote triage: To evaluate and compare between the two groups the number of patient initiated inquiries that result in emergency room (ER)/ clinic visits
undefinedundefined
Clinical Sites
  • 102 sites in USA
undefinedundefined
Sample Size
  • 1.450 patients enrolled
undefinedundefined
Inclusion Criteria
  • mplanted within 45 days prior to enrollment or being considered for implantation of a BIOTRONIK Lumax/ Lumos ICD with Home Monitoring technology
  • Ability to use HM system
  • Ability to give informed consent
  • Ability to return to clinic for protocol required follow-ups for 15 months
  • At least 18 years old
undefinedundefined
Main Exclusion Criteria
  • Patients who were pacemaker dependent when being considered for enrollment
  • Patients who were enrolled in any other cardiac clinical investigation when being considered for enrollment
  • Patients who did not fulfill all inclusion criteria
undefinedundefined
Devices
  • Patients were implanted with Lumax VR-T/DR-T or Lumos VR-T/DR-T
undefinedundefined
Study FlowchartFlow Chart Study Design TRUST
Study Duration
  • Patient participation and follow up period: up to 15 months
undefinedundefined
Principal Investigators
  • Niraj Varma, M.D. (Principal Investigator, Cleveland Clinic, Cleveland, OH)
  • Andrew Epstein, M.D. (University of Pennsylvania, PA)
  • Venkateshwar Gottipaty, M.D. (South Carolina Heart, Columbia, SC)
  • Shumel Inbar, M.D. (Odessa, TX)
  • John Ip, M.D. (Ingham Hospital, Lansing, MI)
  • Charles Love, M.D. (Ohio State University, Columbus, OH)
  • Suresh Neelagaru, M.D. (Lone Star Arrhythmia & HF, Amarillo, TX)
  • Farrell Pierson, M.D.( Knoxville, TN) and Robert Schweikert, M.D. (Cleveland Clinic, Cleveland, OH
undefinedundefined

Downloads


Related Products

Tachycardia Therapy

Tachycardia Therapy

BIOTRONIK offers an extensive product portfolio in the area of tachycardia therapy.

BIOTRONIK Home Monitoring

Cardiac Remote Monitoring

BIOTRONIK offers Home Monitoring for its complete product portfolio.